研究单位：[1]Guangzhou University of Traditional Chinese Medicine[2]Guangdong Provincial Hospital of Chinese Medicine Guangzhou,Guangdong,China,510120
研究目的：
Determine the maximum tolerable dose (MTD) and / or phase II recommended dose (RP2D) of the allotinib combined mXELIRI protocol.
To evaluate the safety and tolerance of the combination of anlotinib and mXELIRI in the second-line treatment of patients with advanced colorectal cancer
